<p>SOPHiA GENETICS SA（納斯達克代碼：SOPH - 獲取免費報告）在十月份經歷了顯著的空頭頭寸下降。截至 10 月 15 日，空頭頭寸總計 21,800 股，較 9 月 30 日的 33,200 股下降了 34.3%。根據 87,500 股的平均日交易量，當前的空頭頭寸比率為 0.2 天。目前，公司 0.0% 的股份被賣空。目前，公司 0.0% 的股份被賣空。根據 87,500 股的平均日交易量，當前的空頭頭寸比率為 0.2 天。</p>
<p>獲取 <strong>SOPHiA GENETICS</strong> 警報：</p>
<h2>對 SOPHiA GENETICS 的對沖基金看法</h2>
<p>一些機構投資者最近買入和賣出了 SOPH 的股票。瑞銀資產管理公司（UBS AM）作為瑞銀資產管理美洲的一個獨立業務單位，在第一季度將其在 SOPHiA GENETICS 的持股增加了 246.9%。瑞銀資產管理公司現在擁有 7,632,871 股公司股票，價值 25,341,000 美元，在此期間又購買了 5,432,871 股。Akre Capital Management LLC 在第二季度將其在 SOPHiA GENETICS 的持股增加了 66.2%。Akre Capital Management LLC 現在擁有 3,719,140 股公司股票，價值 11,529,000 美元，在上個季度又購買了 1,481,636 股。Archon Capital Management LLC 在第二季度購買了 SOPHiA GENETICS 的新頭寸，價值約 997,000 美元。Ensign Peak Advisors Inc 在第二季度購買了 SOPHiA GENETICS 的新頭寸，價值約 775,000 美元。最後，Rathbones Group PLC 在第二季度購買了 SOPHiA GENETICS 的新股份，價值約 504,000 美元。31.59% 的股票由機構投資者持有。</p>
<h2>華爾街分析師看法</h2>
<p>幾家券商最近對 SOPH 發佈了報告。Weiss Ratings 在 10 月 8 日星期三的報告中重申了對 SOPHiA GENETICS 股票的 “賣出（d-）” 評級。Wall Street Zen 在星期六將 SOPHiA GENETICS 的評級上調至 “持有”。一位股票研究分析師對該股票給予了買入評級，另一位則給予了賣出評級。根據 MarketBeat 的數據，該公司的共識評級為 “持有”，共識目標價為 8.00 美元。</p>
<p><strong>查看我們關於 SOPH 的最新報告</strong></p>
<h2>SOPHiA GENETICS 股票表現</h2>
<p>SOPH 的股票在星期五下跌了 0.19 美元，達到 5.00 美元。該公司的股票交易量為 157,207 股，而其平均交易量為 139,344 股。該股票的 50 日簡單移動平均為 3.89 美元，200 日簡單移動平均為 3.41 美元。該公司的債務與股本比率為 0.62，流動比率為 3.39，速動比率為 3.21。該股票的市值為 3.379 億美元，市盈率為-11.36，貝塔值為 1.10。SOPHiA GENETICS 的 12 個月低點為 2.58 美元，12 個月高點為 5.30 美元。</p>
<p>SOPHiA GENETICS（納斯達克代碼：SOPH - 獲取免費報告）最近在 8 月 5 日星期二發佈了季度財報。該公司報告季度每股收益為 0.33 美元，超出共識預期的-0.25 美元，超出幅度為 0.58 美元。該業務在本季度的收入為 1832 萬美元，而共識預期為 1749 萬美元。SOPHiA GENETICS 的淨利潤率為-40.99%，股本回報率為-30.69%。SOPHiA GENETICS 已設定 2025 財年的每股收益指引。研究分析師預測 SOPHiA GENETICS 在當前財年將發佈-0.96 美元的每股收益。</p>
<h2>SOPHiA GENETICS 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>SOPHiA GENETICS SA 作為一家雲原生軟件技術公司在醫療保健領域運營。該公司提供 SOPHiA DDM 平台，這是一個用於分析數據和從多模態數據集及診斷方式中生成洞察的雲原生軟件平台。其 SOPHiA DDM 平台及相關解決方案、應用、產品和服務通過其自有銷售團隊以及在瑞士、法國、意大利、歐洲其他地區、北美、美國、拉丁美洲和亞太地區的分銷商和行業合作伙伴提供給醫院、實驗室和生物製藥公司。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 SOPHiA GENETICS</li>
<li>什麼是低市盈率，它對投資者意味着什麼？</li>
<li>Lemonade 股票在財報後是否會迎來大幅反彈？</li>
<li>3 只可以幫助抵禦通貨膨脹的食品雜貨股票</li>
<li>Caterpillar 股票可能在年底前超過 650 美元</li>
<li>3 只值得長期持有的 REITs</li>
<li>ServiceNow 的 5 比 1 拆股是投資者買入的信號</li>
</ul>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 SOPHiA GENETICS 嗎？</h2>
<p>在考慮 SOPHiA GENETICS 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每天推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前買入……而 SOPHiA GENETICS 並不在名單上。</p>
<p>雖然 SOPHiA GENETICS 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

SOPH

<p>SOPHiA GENETICS SA (NASDAQ:SOPH) 在十月份的空頭頭寸下降了 34.3%，截至 10 月 15 日，共有 21,800 股被賣空。覆蓋天數比率為 0.2 天，表明空頭賣出活動較低。機構投資者持有該股票的 31.59%，瑞銀資產管理顯著增加了其持股比例。分析師的評級意見不一，普遍評級為 “持有”，目標價為 8.00 美元。該股票目前交易價格為 5.00 美元，市值為 3.379 億美金，市盈率為-11.36。公司在上個季度報告的收益好於預期</p>

<p>SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totaling 21,800 shares, a decline of 34.3% from the September 30th total of 33,200 shares. Based on an average daily volume of 87,500 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 87,500 shares, the short-interest ratio is currently 0.2 days.</p>
<div class="lb-trans"><p>SOPHiA GENETICS SA（納斯達克代碼：SOPH - 獲取免費報告）在十月份經歷了顯著的空頭頭寸下降。截至 10 月 15 日，空頭頭寸總計 21,800 股，較 9 月 30 日的 33,200 股下降了 34.3%。根據 87,500 股的平均日交易量，當前的空頭頭寸比率為 0.2 天。目前，公司 0.0% 的股份被賣空。目前，公司 0.0% 的股份被賣空。根據 87,500 股的平均日交易量，當前的空頭頭寸比率為 0.2 天。</p>
</div><p>Get <strong>SOPHiA GENETICS</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>SOPHiA GENETICS</strong> 警報：</p>
</div><h2>Hedge Funds Weigh In On SOPHiA GENETICS</h2>
<div class="lb-trans"><h2>對 SOPHiA GENETICS 的對沖基金看法</h2>
</div><p>A number of institutional investors have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock valued at $25,341,000 after purchasing an additional 5,432,871 shares during the period. Akre Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock valued at $11,529,000 after buying an additional 1,481,636 shares in the last quarter. Archon Capital Management LLC purchased a new position in shares of SOPHiA GENETICS during the 2nd quarter valued at about $997,000. Ensign Peak Advisors Inc bought a new position in shares of SOPHiA GENETICS during the 2nd quarter valued at approximately $775,000. Finally, Rathbones Group PLC purchased a new stake in SOPHiA GENETICS in the 2nd quarter worth approximately $504,000. 31.59% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些機構投資者最近買入和賣出了 SOPH 的股票。瑞銀資產管理公司（UBS AM）作為瑞銀資產管理美洲的一個獨立業務單位，在第一季度將其在 SOPHiA GENETICS 的持股增加了 246.9%。瑞銀資產管理公司現在擁有 7,632,871 股公司股票，價值 25,341,000 美元，在此期間又購買了 5,432,871 股。Akre Capital Management LLC 在第二季度將其在 SOPHiA GENETICS 的持股增加了 66.2%。Akre Capital Management LLC 現在擁有 3,719,140 股公司股票，價值 11,529,000 美元，在上個季度又購買了 1,481,636 股。Archon Capital Management LLC 在第二季度購買了 SOPHiA GENETICS 的新頭寸，價值約 997,000 美元。Ensign Peak Advisors Inc 在第二季度購買了 SOPHiA GENETICS 的新頭寸，價值約 775,000 美元。最後，Rathbones Group PLC 在第二季度購買了 SOPHiA GENETICS 的新股份，價值約 504,000 美元。31.59% 的股票由機構投資者持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師看法</h2>
</div><p>Several brokerages recently issued reports on SOPH. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of SOPHiA GENETICS in a report on Wednesday, October 8th. Wall Street Zen raised SOPHiA GENETICS to a &#34;hold&#34; rating in a report on Saturday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of &#34;Hold&#34; and a consensus target price of $8.00.</p>
<div class="lb-trans"><p>幾家券商最近對 SOPH 發佈了報告。Weiss Ratings 在 10 月 8 日星期三的報告中重申了對 SOPHiA GENETICS 股票的 “賣出（d-）” 評級。Wall Street Zen 在星期六將 SOPHiA GENETICS 的評級上調至 “持有”。一位股票研究分析師對該股票給予了買入評級，另一位則給予了賣出評級。根據 MarketBeat 的數據，該公司的共識評級為 “持有”，共識目標價為 8.00 美元。</p>
</div><p><strong>Check Out Our Latest Report on SOPH</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 SOPH 的最新報告</strong></p>
</div><h2>SOPHiA GENETICS Stock Performance</h2>
<div class="lb-trans"><h2>SOPHiA GENETICS 股票表現</h2>
</div><p>Shares of SOPH traded down $0.19 on Friday, reaching $5.00. The company's stock had a trading volume of 157,207 shares, compared to its average volume of 139,344. The stock's 50 day simple moving average is $3.89 and its two-hundred day simple moving average is $3.41. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.39 and a quick ratio of 3.21. The stock has a market capitalization of $337.90 million, a P/E ratio of -11.36 and a beta of 1.10. SOPHiA GENETICS has a 12-month low of $2.58 and a 12-month high of $5.30.</p>
<div class="lb-trans"><p>SOPH 的股票在星期五下跌了 0.19 美元，達到 5.00 美元。該公司的股票交易量為 157,207 股，而其平均交易量為 139,344 股。該股票的 50 日簡單移動平均為 3.89 美元，200 日簡單移動平均為 3.41 美元。該公司的債務與股本比率為 0.62，流動比率為 3.39，速動比率為 3.21。該股票的市值為 3.379 億美元，市盈率為-11.36，貝塔值為 1.10。SOPHiA GENETICS 的 12 個月低點為 2.58 美元，12 個月高點為 5.30 美元。</p>
</div><p>SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.58. The business had revenue of $18.32 million for the quarter, compared to the consensus estimate of $17.49 million. SOPHiA GENETICS had a negative net margin of 40.99% and a negative return on equity of 30.69%. SOPHiA GENETICS has set its FY 2025 guidance at EPS. Research analysts forecast that SOPHiA GENETICS will post -0.96 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>SOPHiA GENETICS（納斯達克代碼：SOPH - 獲取免費報告）最近在 8 月 5 日星期二發佈了季度財報。該公司報告季度每股收益為 0.33 美元，超出共識預期的-0.25 美元，超出幅度為 0.58 美元。該業務在本季度的收入為 1832 萬美元，而共識預期為 1749 萬美元。SOPHiA GENETICS 的淨利潤率為-40.99%，股本回報率為-30.69%。SOPHiA GENETICS 已設定 2025 財年的每股收益指引。研究分析師預測 SOPHiA GENETICS 在當前財年將發佈-0.96 美元的每股收益。</p>
</div><h2>SOPHiA GENETICS Company Profile</h2>
<div class="lb-trans"><h2>SOPHiA GENETICS 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.</p>
<div class="lb-trans"><p>SOPHiA GENETICS SA 作為一家雲原生軟件技術公司在醫療保健領域運營。該公司提供 SOPHiA DDM 平台，這是一個用於分析數據和從多模態數據集及診斷方式中生成洞察的雲原生軟件平台。其 SOPHiA DDM 平台及相關解決方案、應用、產品和服務通過其自有銷售團隊以及在瑞士、法國、意大利、歐洲其他地區、北美、美國、拉丁美洲和亞太地區的分銷商和行業合作伙伴提供給醫院、實驗室和生物製藥公司。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than SOPHiA GENETICS</li>
<li>What is a Low P/E Ratio and What Does it Tell Investors?</li>
<li>Is Lemonade Stock Set for a Big Squeeze After Earnings?</li>
<li>3 Grocery Stocks That Can Help Take a Bite Out of Inflation</li>
<li>Caterpillar Stock Could Top $650 by Year’s End</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>ServiceNow’s 5-for-1 Split Is a Signal for Investors to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 SOPHiA GENETICS</li>
<li>什麼是低市盈率，它對投資者意味着什麼？</li>
<li>Lemonade 股票在財報後是否會迎來大幅反彈？</li>
<li>3 只可以幫助抵禦通貨膨脹的食品雜貨股票</li>
<li>Caterpillar 股票可能在年底前超過 650 美元</li>
<li>3 只值得長期持有的 REITs</li>
<li>ServiceNow 的 5 比 1 拆股是投資者買入的信號</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in SOPHiA GENETICS Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 SOPHiA GENETICS 嗎？</h2>
</div><p>Before you consider SOPHiA GENETICS, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 SOPHiA GENETICS 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SOPHiA GENETICS wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每天推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前買入……而 SOPHiA GENETICS 並不在名單上。</p>
</div><p>While SOPHiA GENETICS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 SOPHiA GENETICS 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

SOPHiA GENETICS SA（NASDAQ 代碼：SOPH）空頭頭寸更新